Akari Therapeutics (NASDAQ:AKTX) Stock Price Passes Below 200 Day Moving Average of $2.47

Shares of Akari Therapeutics, Plc (NASDAQ:AKTX) crossed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $2.47 and traded as low as $1.52. Akari Therapeutics shares last traded at $1.64, with a volume of 30,367 shares.

Wall Street Analysts Forecast Growth

Separately, StockNews.com began coverage on Akari Therapeutics in a research report on Thursday, May 2nd. They issued a “sell” rating on the stock.

Akari Therapeutics Trading Up 12.8 %

The stock has a fifty day moving average price of $1.63 and a 200-day moving average price of $2.47.

Institutional Investors Weigh In On Akari Therapeutics

A hedge fund recently raised its stake in Akari Therapeutics stock. Omnia Family Wealth LLC lifted its holdings in shares of Akari Therapeutics, Plc (NASDAQ:AKTX) by 48.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 87,628 shares of the biopharmaceutical company’s stock after acquiring an additional 28,511 shares during the quarter. Omnia Family Wealth LLC owned about 1.55% of Akari Therapeutics worth $273,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 5.06% of the company’s stock.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.